Mucosal immune responses to Bordetella pertussis in Gambian infants after maternal and primary vaccination: an immunological substudy of a single-centre, randomised, controlled, double-blind, phase 4 trial
The Lancet Microbe · 2026-01 · 7 (1) · 101219
DOI: 10.1016/j.lanmic.2025.101219 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Lancet Microbe, 2026-01. Verfasst von Anja Saso und 21 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia; Faculty of Infectious and T…. Hauptthemen laut MEDLINE: Bordetella pertussis, Whooping Cough, Immunity, Mucosal, Pertussis Vaccine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Bill and Melinda Gates Foundation, Innovative Medicines Initiative.
Abstract (Originalsprache)
BACKGROUND: Mucosal protection against pertussis depends on antibodies and the activation of mucosal-resident memory T cells, both of which are differentially induced by acellular pertussis and whole-cell pertussis vaccines. We aimed to investigate the effect of primary vaccination with these two vaccine types on pertussis-specific mucosal immunity in infants after their mothers received an acellular pertussis-containing vaccine (tetanus-diphtheria-acellular pertussis-inactivated poliovirus; Tdap-IPV) or a tetanus-toxoid (TT)-only vaccine during pregnancy. METHODS: This immunological substudy was embedded within the Gambian Pertussis Study (GaPs), a single-centre, randomised, controlled, double-blind, phase 4 trial conducted in The Gambia. In GaPs, healthy, pregnant participants aged 18-40 years were randomly assigned (1:1) to receive a pertussis-containing (Tdap-IPV) vaccine or a TT-only vaccine at 28-34 weeks' gestation, and their infants were randomly assigned (1:1) to receive a primary immunisation series comprising either a diphtheria-tetanus-whole-cell pertussis (DTwP) vaccine or a diphtheria-tetanus-acellular pertussis (DTaP) vaccine at the ages of 8, 12, and 16 weeks. Nasosorption devices were used to collect nasal mucosal lining fluid (MLF) from infants at the ages of 8, 16, 17, and 20 weeks, and 9 months. The immunological substudy was conducted in a subset of infants in the GaPs trial for whom MLF and paired cord blood and serum samples were available; outcomes were the concentrations of nasal anti-B pertussis IgG and IgA and anti-pertussis toxin IgG, before and after the DTaP or DTwP primary immunisation series at the ages of 8 weeks, 20 weeks, and 9 months, and the concentrations of nasal T-cell-associated cytokines at age 17 weeks. This study is registered with ClinicalTrials.gov, NCT03606096. FINDINGS: This substudy included 160 infants enrolled in the main GaPs trial between Feb 13, 2019, and May 17, 2021. At age 8 weeks, before primary vaccination, infants born to mothers who had received the Tdap-IPV vaccine in pregnancy had higher concentrations of maternally derived nasal anti-pertussis toxin IgG (geometric mean ratio 3·84 [95% CI 3·22-4·59]; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London…
- Laboratory of Medical Immunology, Radboudumc, Nijmegen, Netherlands; Radboud Community for Infectious Diseases, Radboudumc, Nijmegen, Netherlands.
- Vaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia.
- Department of Medical BioSciences, Radboudumc, Nijmegen, Netherlands.
- Laboratory of Medical Immunology, Radboudumc, Nijmegen, Netherlands; Radboud Community for Infectious Diseases, Radboudumc, Nijmegen, Netherlands. Electronic address: dimitri.diavatopoulos@radboudumc.nl.
Förderung
- Wellcome Trust
- Bill and Melinda Gates Foundation
- Innovative Medicines Initiative
- European Federation of Pharmaceutical Industries and Associations
- Horizon 2020 Framework Programme
Zitieren
APA
Saso, A., Fröberg, J., Jobe, H., Eleveld, M., Okoye, M., Kanteh, E., Arns, A., van Opzeeland, F., Kumado, M., Faal, A., Roberts, E., Fofana, M. L., Baldeh, A. K., Conteh, K., van Cranenbroek, B., Roetynck, S., de Jonge, M., de Silva, T. I., Huynen, M., …, & GaPs Study Team (2026). Mucosal immune responses to Bordetella pertussis in Gambian infants after maternal and primary vaccination: an immunological substudy of a single-centre, randomised, controlled, double-blind, phase 4 trial. The Lancet Microbe, 7(1), 101219. https://doi.org/10.1016/j.lanmic.2025.101219
Vancouver
Saso A, Fröberg J, Jobe H, Eleveld M, Okoye M, Kanteh E, et al. Mucosal immune responses to Bordetella pertussis in Gambian infants after maternal and primary vaccination: an immunological substudy of a single-centre, randomised, controlled, double-blind, phase 4 trial. The Lancet Microbe. 2026;7(1):101219. doi:10.1016/j.lanmic.2025.101219
BibTeX
@article{Saso2026,
author = {Saso, Anja and Fröberg, Janeri and Jobe, Haddijatou and Eleveld, Marc and Okoye, Michael and Kanteh, Ebrima and Arns, Annemijn and van Opzeeland, Fred and Kumado, Michelle and Faal, Amadou and Roberts, Elishia and Fofana, Modou-Lamin and Baldeh, Aru-Kumba and Conteh, Karamo and van Cranenbroek, Bram and Roetynck, Sophie and de Jonge, Marien and de Silva, Thushan I and Huynen, Martijn and Kampmann, Beate and Diavatopoulos, Dimitri A and GaPs Study Team, GaPs Study Team},
title = {Mucosal immune responses to Bordetella pertussis in Gambian infants after maternal and primary vaccination: an immunological substudy of a single-centre, randomised, controlled, double-blind, phase 4 trial},
journal = {The Lancet Microbe},
year = {2026},
volume = {7},
number = {1},
pages = {101219},
doi = {10.1016/j.lanmic.2025.101219}
}
EUVIMED